With more KRAS inhibitors in clinical development and combination therapies of KRAS inhibition and immunotherapy, there is an unmet need to characterize the immunological features of patients with KRAS mutated lung cancer to facilitate translational studies. Here, KRAS is linked to lung carcinoma.